NASDAQ:CYTR - CytRx Stock Price, Price Target & More

$1.69 -0.04 (-2.31 %)
(As of 04/20/2018 12:18 PM ET)
Previous Close$1.73
Today's Range$1.65 - $1.75
52-Week Range$1.43 - $6.00
Volume112,376 shs
Average Volume365,838 shs
Market Capitalization$49.91 million
P/E RatioN/A
Dividend YieldN/A
Beta2.05

About CytRx (NASDAQ:CYTR)

CytRx logoCytRx Corporation operates as a biopharmaceutical research and development company specializing in oncology. The company's product candidate is the aldoxorubicin, which is in Phase III clinical trial as a therapy for patients with soft tissue sarcomas (STS) whose tumors have progressed following treatment with chemotherapy; in Phase IIb clinical trial in small cell lung cancer; in Phase II clinical trial in HIV-related Kaposi's sarcoma; in Phase II clinical trial in patients with late-stage glioblastoma (brain cancer); in Phase Ib trial in combination with ifosfamide in patients with STS; and in Phase Ib trial in combination with gemcitabine in subjects with metastatic solid tumors. It also has completed Phase IIb and Phase Ib/II clinical trials with aldoxorubicin as a first-line therapy for STS; a Phase Ib clinical trial of aldoxorubicin in combination with doxorubicin in patients with advanced solid tumors; and a Phase Ib pharmacokinetics clinical trial in patients with metastatic solid tumors. The company is also developing anti-cancer drug conjugates, which utilizes its Linker Activated Drug Release technology. CytRx Corporation was founded in 1985 and is headquartered in Los Angeles, California.

Receive CYTR News and Ratings via Email

Sign-up to receive the latest news and ratings for CYTR and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:CYTR
CUSIPN/A
Phone310-826-5648

Debt

Debt-to-Equity RatioN/A
Current Ratio1.56%
Quick Ratio1.56%

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual Sales$100,000.00
Price / Sales473.88
Cash FlowN/A
Price / CashN/A
Book Value$0.66 per share
Price / Book2.56

Profitability

EPS (Most Recent Fiscal Year)N/A
Net Income$-34,980,000.00
Net MarginsN/A
Return on Equity-187.35%
Return on Assets-65.74%

Miscellaneous

Employees20
Outstanding Shares28,040,000

How to Become a New Pot Stock Millionaire

CytRx (NASDAQ:CYTR) Frequently Asked Questions

What is CytRx's stock symbol?

CytRx trades on the NASDAQ under the ticker symbol "CYTR."

When did CytRx's stock split? How did CytRx's stock split work?

CytRx shares reverse split before market open on Wednesday, November 1st 2017. The 1-6 reverse split was announced on Friday, October 27th 2017. The number of shares owned by shareholders was adjusted after the market closes on Tuesday, October 31st 2017. An investor that had 100 shares of CytRx stock prior to the reverse split would have 17 shares after the split.

How were CytRx's earnings last quarter?

CytRx (NASDAQ:CYTR) announced its quarterly earnings results on Monday, March, 19th. The biotechnology company reported ($0.16) earnings per share for the quarter. The biotechnology company earned $0.10 million during the quarter. View CytRx's Earnings History.

When is CytRx's next earnings date?

CytRx is scheduled to release their next quarterly earnings announcement on Wednesday, May, 9th 2018. View Earnings Estimates for CytRx.

What price target have analysts set for CYTR?

1 Wall Street analysts have issued 1 year price objectives for CytRx's shares. Their forecasts range from $24.00 to $24.00. On average, they anticipate CytRx's stock price to reach $24.00 in the next twelve months. View Analyst Ratings for CytRx.

Who are some of CytRx's key competitors?

Who are CytRx's key executives?

CytRx's management team includes the folowing people:
  • Mr. Steven A. Kriegsman, Chairman, Chief Exec. Officer and Pres (Age 76)
  • Mr. John Y. Caloz, CFO, Chief Accounting Officer & Treasurer (Age 66)
  • Dr. Bruce Spiegelman Ph.D., Member of Scientific Advisory Board of CytRx Laboratories Inc
  • Dr. Luciano Rossetti M.D., Member of Scientific Advisory Board of CytRx Laboratories Inc
  • Dr. Felix Kratz Ph.D., Sr. VP, Drug Devel. (Age 55)

Has CytRx been receiving favorable news coverage?

News coverage about CYTR stock has trended somewhat positive on Friday, Accern Sentiment reports. Accern scores the sentiment of press coverage by monitoring more than 20 million news and blog sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores nearest to one being the most favorable. CytRx earned a coverage optimism score of 0.04 on Accern's scale. They also assigned media headlines about the biotechnology company an impact score of 46.33 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the stock's share price in the near future.

How do I buy shares of CytRx?

Shares of CYTR can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is CytRx's stock price today?

One share of CYTR stock can currently be purchased for approximately $1.69.

How big of a company is CytRx?

CytRx has a market capitalization of $49.91 million and generates $100,000.00 in revenue each year. CytRx employs 20 workers across the globe.

How can I contact CytRx?

CytRx's mailing address is 11726 SAN VICENTE BOULEVARD SUITE 650, LOS ANGELES CA, 90049. The biotechnology company can be reached via phone at 310-826-5648 or via email at [email protected]


MarketBeat Community Rating for CytRx (CYTR)

Community Ranking:  3.0 out of 5 (star star star)
Outperform Votes:  249 (Vote Outperform)
Underperform Votes:  162 (Vote Underperform)
Total Votes:  411
MarketBeat's community ratings are surveys of what our community members think about CytRx and other stocks. Vote "Outperform" if you believe CYTR will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CYTR will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

CytRx (NASDAQ:CYTR) Price Target and Consensus Rating

  (How are Consensus Ratings Calculated?)
1 Wall Street analysts have issued ratings and price targets for CytRx in the last 12 months. Their average twelve-month price target is $24.00, suggesting that the stock has a possible upside of 1,320.12%. The high price target for CYTR is $24.00 and the low price target for CYTR is $24.00. There are currently 1 buy rating for the stock, resulting in a consensus rating of "Buy."
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 3.003.003.003.00
Ratings Breakdown: 0 Sell Rating(s)
0 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $24.00$24.00$24.00$21.00
Price Target Upside: 1,320.12% upside396.46% upside396.46% upside334.40% upside

CytRx (NASDAQ:CYTR) Consensus Price Target History

Price Target History for CytRx (NASDAQ:CYTR)

CytRx (NASDAQ:CYTR) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
4/26/2017HC WainwrightReiterated RatingBuy$24.00HighView Rating Details
3/21/2017AegisReiterated RatingBuyMediumView Rating Details
11/14/2016FBR & CoSet Price TargetBuy$18.00N/AView Rating Details
7/15/2016Jefferies GroupReiterated RatingHold$15.00 -> $4.50N/AView Rating Details
7/12/2016S&P Equity ResearchLower Price Target$6.24 -> $4.50N/AView Rating Details
(Data available from 4/20/2016 forward)

Earnings

CytRx (NASDAQ:CYTR) Earnings History and Estimates Chart

Earnings by Quarter for CytRx (NASDAQ:CYTR)

CytRx (NASDAQ CYTR) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/8/2018N/AView Earnings Details
3/19/2018Q4 2017($0.16)$0.10 millionViewListenView Earnings Details
11/8/2017Q3 2017($0.33)ViewN/AView Earnings Details
8/3/2017Q2 2017($0.42)ViewN/AView Earnings Details
5/10/2017Q1 2017($0.60)ViewN/AView Earnings Details
3/15/2017Q4 2016($0.66)($0.60)$0.10 millionViewN/AView Earnings Details
11/9/2016Q3 2016($0.96)($0.78)ViewN/AView Earnings Details
7/29/2016Q2($1.14)($1.62)$0.10 millionViewN/AView Earnings Details
5/11/2016Q116($1.56)($1.14)ViewN/AView Earnings Details
3/11/2016Q4 2015($1.20)($2.10)$0.10 millionViewN/AView Earnings Details
11/3/2015Q315($1.44)($1.02)ViewN/AView Earnings Details
8/3/2015Q215($1.62)($1.50)ViewN/AView Earnings Details
5/1/2015Q115($1.26)($1.68)ViewN/AView Earnings Details
3/10/2015Q4 2014($1.62)($1.44)$0.10 millionViewN/AView Earnings Details
11/4/2014Q314($1.50)($0.60)ViewN/AView Earnings Details
8/6/2014Q214($1.20)($1.68)ViewN/AView Earnings Details
5/1/2014Q1 2014($1.08)ViewN/AView Earnings Details
3/5/2014($1.02)($1.50)$0.10 millionViewN/AView Earnings Details
10/29/2013Q313($1.32)($1.98)$0.20 millionViewN/AView Earnings Details
8/6/2013Q2 2013($1.14)($0.66)$0.20 millionViewN/AView Earnings Details
5/9/2013Q113($0.90)($1.38)ViewN/AView Earnings Details
3/11/2013Q4 2012($1.20)($1.26)ViewN/AView Earnings Details
11/9/2012Q312$0.42ViewN/AView Earnings Details
8/9/2012Q2 2012($1.86)($1.34)ViewN/AView Earnings Details
5/10/2012Q1 2012($1.68)($1.76)ViewN/AView Earnings Details
3/13/2012Q4 2011($1.68)($1.72)ViewN/AView Earnings Details
11/8/2011Q3 2011($1.68)($1.05)ViewN/AView Earnings Details
8/9/2011Q2 2011($2.10)($1.43)ViewN/AView Earnings Details
5/5/2011Q1 2011($1.26)($2.60)ViewN/AView Earnings Details
3/11/2011Q4 2010$2.27ViewN/AView Earnings Details
11/8/2010Q3 2010($2.10)($1.68)ViewN/AView Earnings Details
8/9/2010Q2 2010($2.10)($1.89)ViewN/AView Earnings Details
5/6/2010Q1 2010($1.68)($1.81)ViewN/AView Earnings Details
3/15/2010Q4 2009($1.68)($1.26)ViewN/AView Earnings Details
11/9/2009Q3 2009$0.42$1.51ViewN/AView Earnings Details
8/10/2009Q2 2009($1.68)($1.01)ViewN/AView Earnings Details
5/12/2009Q1 2009($1.68)($1.81)ViewN/AView Earnings Details
3/13/2009Q4 2008($1.68)($1.76)ViewN/AView Earnings Details
11/7/2008Q3 2008($1.68)($1.34)ViewN/AView Earnings Details
8/12/2008Q2 2008($2.52)($1.68)ViewN/AView Earnings Details
5/20/2008Q1 2008($3.36)($2.85)ViewN/AView Earnings Details
4/2/2008Q4 2007($2.94)ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Dividends

CytRx (NASDAQ:CYTR) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

CytRx (NASDAQ CYTR) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 5.30%
Institutional Ownership Percentage: 6.13%
Insider Trading History for CytRx (NASDAQ:CYTR)
Institutional Ownership by Quarter for CytRx (NASDAQ:CYTR)

CytRx (NASDAQ CYTR) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
12/3/2013Scott Bradford Pattersonmajor shareholderBuy284,979$2.44$695,348.764,912,584View SEC Filing  
11/7/2013Scott Bradford PattersonMajor ShareholderBuy50,000$2.06$103,000.00View SEC Filing  
4/1/2013Scott Bradford PattersonMajor ShareholderBuy4,083$2.70$11,024.10View SEC Filing  
3/20/2013Scott Bradford PattersonMajor ShareholderBuy3,980$2.61$10,387.80View SEC Filing  
3/13/2013Scott Bradford PattersonMajor ShareholderBuy55,360$2.67$147,811.20View SEC Filing  
10/22/2012Scott Bradford PattersonMajor ShareholderBuy180,000$2.51$451,800.00View SEC Filing  
10/18/2012Scott Bradford PattersonMajor ShareholderBuy1,200,000$2.50$3,000,000.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

CytRx (NASDAQ CYTR) News Headlines

Source:
DateHeadline
CytRx (CYTR) Upgraded to Sell by ValuEngineCytRx (CYTR) Upgraded to Sell by ValuEngine
www.americanbankingnews.com - April 18 at 4:44 PM
BRIEF-Cytrx Presents Statistically Significant Breakthrough Data For Its Albumin Binding Ultra High Potency Ladr Drug ...BRIEF-Cytrx Presents Statistically Significant Breakthrough Data For Its Albumin Binding Ultra High Potency Ladr Drug ...
www.reuters.com - April 18 at 10:06 AM
CytRx Presents Statistically Significant Breakthrough Data for Its Albumin Binding Ultra High Potency LADR™ Drug ...CytRx Presents Statistically Significant Breakthrough Data for Its Albumin Binding Ultra High Potency LADR™ Drug ...
www.prnewswire.com - April 18 at 10:06 AM
CytRx Presents Statistically Significant Breakthrough Data for Its Albumin Binding Ultra High Potency LADR™ Drug Candidates at the American Association for Cancer Research 2018 Annual MeetingCytRx Presents Statistically Significant Breakthrough Data for Its Albumin Binding Ultra High Potency LADR™ Drug Candidates at the American Association for Cancer Research 2018 Annual Meeting
finance.yahoo.com - April 18 at 10:06 AM
CytRx (CYTR) Rating Lowered to Sell at ValuEngineCytRx (CYTR) Rating Lowered to Sell at ValuEngine
www.americanbankingnews.com - April 13 at 1:35 PM
CytRx Corporation to Present Breakthrough Data on Albumin Binding Ultra High Potency LADR™ Drug Candidates at ...CytRx Corporation to Present Breakthrough Data on Albumin Binding Ultra High Potency LADR™ Drug Candidates at ...
www.prnewswire.com - April 9 at 10:23 AM
CytRx Corporation to Present Breakthrough Data on Albumin Binding Ultra High Potency LADR™ Drug Candidates at the AACR 2018 ConferenceCytRx Corporation to Present Breakthrough Data on Albumin Binding Ultra High Potency LADR™ Drug Candidates at the AACR 2018 Conference
finance.yahoo.com - April 9 at 10:23 AM
CytRx (CYTR) Downgraded by ValuEngine to "Strong Sell"CytRx (CYTR) Downgraded by ValuEngine to "Strong Sell"
www.americanbankingnews.com - March 31 at 2:40 PM
Edited Transcript of CYTR earnings conference call or presentation 19-Mar-18 3:00pm GMTEdited Transcript of CYTR earnings conference call or presentation 19-Mar-18 3:00pm GMT
finance.yahoo.com - March 29 at 10:29 AM
CytRx (CYTR) Reports Q4 Loss of $1.46CytRx (CYTR) Reports Q4 Loss of $1.46
www.streetinsider.com - March 19 at 10:37 AM
CytRx Corporation to Host Earnings CallCytRx Corporation to Host Earnings Call
finance.yahoo.com - March 19 at 10:37 AM
CytRx reports 4Q lossCytRx reports 4Q loss
finance.yahoo.com - March 19 at 10:37 AM
CytRx Reports 2017 Financial ResultsCytRx Reports 2017 Financial Results
finance.yahoo.com - March 19 at 10:37 AM
CytRx (CYTR) Issues Quarterly  Earnings ResultsCytRx (CYTR) Issues Quarterly Earnings Results
www.americanbankingnews.com - March 19 at 7:20 AM
CytRx to Present at the 28th Annual Oppenheimer Healthcare Conference - PR Newswire (press release)CytRx to Present at the 28th Annual Oppenheimer Healthcare Conference - PR Newswire (press release)
www.prnewswire.com - March 16 at 4:13 PM
CytRx to Present at the 28th Annual Oppenheimer Healthcare ConferenceCytRx to Present at the 28th Annual Oppenheimer Healthcare Conference
finance.yahoo.com - March 16 at 10:58 AM
BRIEF-CytRx Selects Four New LADR™ Ultra High Potency Drug Candidates For Advancement Toward Clinical TrialsBRIEF-CytRx Selects Four New LADR™ Ultra High Potency Drug Candidates For Advancement Toward Clinical Trials
www.reuters.com - March 15 at 10:51 AM
CytRx Selects Four New LADR™ Ultra High Potency Drug Candidates for Advancement Toward Clinical TrialsCytRx Selects Four New LADR™ Ultra High Potency Drug Candidates for Advancement Toward Clinical Trials
finance.yahoo.com - March 15 at 10:51 AM
CytRx to Hold Year End 2017 Financial Results Conference Call and Webcast on Monday, March 19, 2018CytRx to Hold Year End 2017 Financial Results Conference Call and Webcast on Monday, March 19, 2018
finance.yahoo.com - March 12 at 4:02 PM
CytRx (CYTR) to Release Quarterly Earnings on TuesdayCytRx (CYTR) to Release Quarterly Earnings on Tuesday
www.americanbankingnews.com - March 6 at 2:32 AM
CytRx to Present at the 30th Annual ROTH ConferenceCytRx to Present at the 30th Annual ROTH Conference
finance.yahoo.com - March 5 at 10:59 AM
Are Earnings Prospects Improving For Loss-Making CytRx Corporation’s (NASDAQ:CYTR)?Are Earnings Prospects Improving For Loss-Making CytRx Corporation’s (NASDAQ:CYTR)?
finance.yahoo.com - March 3 at 10:36 AM
CytRx Announces Key Addition to Corporate Development TeamCytRx Announces Key Addition to Corporate Development Team
finance.yahoo.com - March 1 at 10:03 AM
CytRx hires advisor to assist in identifying partnering opportunities for LADR conjugatesCytRx hires advisor to assist in identifying partnering opportunities for LADR conjugates
seekingalpha.com - February 28 at 4:11 PM
BRIEF-Cytrx Corp Announces Its Entry Into A Definitive Agreement With Destum PartnersBRIEF-Cytrx Corp Announces Its Entry Into A Definitive Agreement With Destum Partners
www.reuters.com - February 28 at 10:30 AM
CytRx Announces Expansion of Pharma Partnering Activities for Its LADR™ Ultra-High Potency Drug CandidatesCytRx Announces Expansion of Pharma Partnering Activities for Its LADR™ Ultra-High Potency Drug Candidates
finance.yahoo.com - February 28 at 10:30 AM
CytRx Announces the Presentation of New LADR™ Candidate Data at the American Association for Cancer Research 2018 Annual MeetingCytRx Announces the Presentation of New LADR™ Candidate Data at the American Association for Cancer Research 2018 Annual Meeting
finance.yahoo.com - February 22 at 9:57 AM
CytRx Corporation to Present at the 2018 BIO CEO & Investor ConferenceCytRx Corporation to Present at the 2018 BIO CEO & Investor Conference
finance.yahoo.com - February 6 at 3:20 PM
CytRx Corporation Highlights Second NantCell Inc. Clinical Trial Evaluating Immuno-Oncology Agents and Cell-based Therapies in Combination with Aldoxorubicin in Patients with Advanced Squamous Cell CarcinomaCytRx Corporation Highlights Second NantCell Inc. Clinical Trial Evaluating Immuno-Oncology Agents and Cell-based Therapies in Combination with Aldoxorubicin in Patients with Advanced Squamous Cell Carcinoma
finance.yahoo.com - February 5 at 3:20 PM
Today’s Research Reports on Stocks to Watch: Inovio Pharmaceuticals and CytRx CorporationToday’s Research Reports on Stocks to Watch: Inovio Pharmaceuticals and CytRx Corporation
finance.yahoo.com - January 24 at 8:49 AM
CytRx Corporation Highlights Dosing of the First Patient in Licensee NantCell Inc. Clinical Trial Investigating Cell-Based Therapy in Combination with Multiple Anti-Cancer Agents, Including Aldoxorubicin, in Patients with Metastatic Pancreatic CancerCytRx Corporation Highlights Dosing of the First Patient in Licensee NantCell Inc. Clinical Trial Investigating Cell-Based Therapy in Combination with Multiple Anti-Cancer Agents, Including Aldoxorubicin, in Patients with Metastatic Pancreatic Cancer
finance.yahoo.com - January 17 at 9:36 AM
CytRx Corporation to Present at Biotech Showcase 2018CytRx Corporation to Present at Biotech Showcase 2018
finance.yahoo.com - January 3 at 5:09 PM
Financial Analysis: CytRx (CYTR) vs. Its PeersFinancial Analysis: CytRx (CYTR) vs. Its Peers
www.americanbankingnews.com - December 11 at 11:26 AM
CytRx Corporation Provides Update on Presentations at Upcoming Investor ConferencesCytRx Corporation Provides Update on Presentations at Upcoming Investor Conferences
finance.yahoo.com - December 7 at 10:00 AM
Comparing CytRx (CYTR) & The CompetitionComparing CytRx (CYTR) & The Competition
www.americanbankingnews.com - December 6 at 11:20 AM
CytRx Corporation Announces Filing of Key Provisional Patent Applications for Ultra-High Potency LADR™ Drug CandidatesCytRx Corporation Announces Filing of Key Provisional Patent Applications for Ultra-High Potency LADR™ Drug Candidates
finance.yahoo.com - December 6 at 9:54 AM
ValuEngine Downgrades CytRx (CYTR) to Strong SellValuEngine Downgrades CytRx (CYTR) to Strong Sell
www.americanbankingnews.com - December 3 at 5:12 PM
Critical Comparison: CytRx (CYTR) versus Its CompetitorsCritical Comparison: CytRx (CYTR) versus Its Competitors
www.americanbankingnews.com - November 29 at 3:20 PM
CytRx Corporation to Present at Upcoming Investor ConferencesCytRx Corporation to Present at Upcoming Investor Conferences
finance.yahoo.com - November 27 at 6:06 PM
Today’s Research Reports on Stocks to Watch: Eleven Biotherapeutics and CytRx CorporationToday’s Research Reports on Stocks to Watch: Eleven Biotherapeutics and CytRx Corporation
finance.yahoo.com - November 20 at 6:43 PM
CytRx (CYTR) Regains Nasdaq Listing ComplianceCytRx (CYTR) Regains Nasdaq Listing Compliance
www.streetinsider.com - November 18 at 5:20 PM
CytRx Corporation Regains Nasdaq Listing Compliance - PR Newswire (press release)CytRx Corporation Regains Nasdaq Listing Compliance - PR Newswire (press release)
www.prnewswire.com - November 17 at 11:39 PM
Contrasting CytRx Corporation (CYTR) and Its CompetitorsContrasting CytRx Corporation (CYTR) and Its Competitors
www.americanbankingnews.com - November 17 at 9:30 PM
Analyzing CytRx Corporation (CYTR) and Its PeersAnalyzing CytRx Corporation (CYTR) and Its Peers
www.americanbankingnews.com - November 17 at 2:08 PM
CytRx Corporation Regains Nasdaq Listing ComplianceCytRx Corporation Regains Nasdaq Listing Compliance
finance.yahoo.com - November 17 at 1:35 PM
CytRx Corporation Provides Business Update and Announces New Shareholder Initiatives - PR Newswire (press release)CytRx Corporation Provides Business Update and Announces New Shareholder Initiatives - PR Newswire (press release)
www.prnewswire.com - November 15 at 4:11 AM
BRIEF-Cytrx announces new shareholder initiativesBRIEF-Cytrx announces new shareholder initiatives
www.reuters.com - November 13 at 12:26 PM
CytRx Corporation Provides Business Update and Announces New Shareholder InitiativesCytRx Corporation Provides Business Update and Announces New Shareholder Initiatives
finance.yahoo.com - November 13 at 12:26 PM
CytRx Reports Third Quarter 2017 Financial Results - PR Newswire (press release)CytRx Reports Third Quarter 2017 Financial Results - PR Newswire (press release)
www.prnewswire.com - November 9 at 5:34 AM
CytRx reports 3Q lossCytRx reports 3Q loss
finance.yahoo.com - November 9 at 12:32 AM

SEC Filings

CytRx (NASDAQ:CYTR) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

CytRx (NASDAQ:CYTR) Income Statement, Balance Sheet and Cash Flow Statement

Chart

CytRx (NASDAQ CYTR) Stock Chart for Friday, April, 20, 2018

Loading chart…

This page was last updated on 4/20/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.